Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLGAB conditioning vs BCNU-based conditioning in autologous HSCT for refractory/recurrent lymphoma
ChiCTR2100042685Phase 4Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cladribine, gemcitabine, cytarabine, busulfan, carmustine and 2 more in lymphoma and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Henan Provincial People's Hospital. Primary endpoints: overall survival, progression-free survival and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
cladribinegemcitabinecytarabinebusulfancarmustine
03
Conditions
lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100042685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042685.